Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells-EGFRvIII Appears as a Weak Oncogene. | Int J Mol Sci | 2022 | 36292985 | PubTator, text mining | PubMed |
| A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma. | Int J Mol Sci | 2022 | 36292980 | PubTator, text mining | PubMed |
| Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. | Cancers (Basel) | 2022 | 36291891 | PubTator, text mining | PubMed |
| Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma. | Cancers (Basel) | 2022 | 36291802 | PubTator, text mining | PubMed |
| Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. | Biomedicines | 2022 | 36289703 | PubTator, text mining | PubMed |
| Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2. | Clin Transl Immunology | 2022 | 36285327 | PubTator, text mining | PubMed |
| Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse. | ACS Nano | 2022 | 36282488 | PubTator, text mining | PubMed |
| Cystine-dependent antiporters buffer against excess intracellular reactive sulfur species-induced stress. | Redox Biol | 2022 | 36279630 | PubTator, text mining | PubMed |
| Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma. | Front Oncol | 2022 | 36276071 | PubTator, text mining | PubMed |
| Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology. | Oncoimmunology | 2022 | 36275862 | PubTator, text mining | PubMed |
| Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma. | Front Immunol | 2022 | 36275715 | PubTator, text mining | PubMed |
| Prospective approaches to enhancing CAR T cell therapy for glioblastoma. | Front Immunol | 2022 | 36275671 | PubTator, text mining | PubMed |
| Nidogen-1 could play a role in diabetic kidney disease development in type 2 diabetes: a genome-wide association meta-analysis. | Hum Genomics | 2022 | 36271454 | PubTator, text mining | PubMed |
| Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory. | Onco Targets Ther | 2022 | 36267609 | PubTator, text mining | PubMed |
| Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma. | Front Mol Biosci | 2022 | 36267158 | PubTator, text mining | PubMed |
| Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function. | Br J Cancer | 2022 | 36266575 | PubTator, text mining | PubMed |
| Targeting inflammation to improve regulatory T cell therapy for immunopathologies. | Proc Natl Acad Sci U S A | 2022 | 36264819 | PubTator, text mining | PubMed |
| Tumor buster - where will the CAR-T cell therapy 'missile' go? | Mol Cancer | 2022 | 36261831 | PubTator, text mining | PubMed |
| Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy. | Cancer Immunol Res | 2022 | 36259217 | PubTator, text mining | PubMed |
| Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. | Adv Sci (Weinh) | 2022 | 36257824 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=53